Lobbying efforts have ensured that long-term care residents and other seniors are commonly prescribed the expensive drug Lucentis, even though the less costly drug Avastin has proven equally effective, suggests a USA TODAY article published Thursday. Lucentis in fact has become the No. 1 drug reimbursed by Medicare.
Long-term care providers and residents now can glean insights into where their local doctors stack up nationally by referring to newly released data on Medicare physician payments. For the first time ever, the government made this information publicly available Wednesday.
Injectable drugs ranibizumab (Lucentis) and bevacizumab (Avastin) help prevent nursing home admissions among those with age-related wet macular degeneration, according to findings in JAMA Ophthalmology.
Injectable drugs introduced in the last decade have proven effective in preserving vision and preventing nursing home admissions among those with age-related wet macular degeneration, according to recently published research.
The cheaper of the two rival macular degeneration treatments could lead to blindness or other adverse events, new research determined.
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.
Injections of the cancer drug Avastin, which is also a treatment for the wet form of age-related macular degeneration, has been linked to reports of blindness.
Further legislation is needed to empower the federal government to negotiate lower prescription drug prices in Medicare, a bipartisan panel concluded Thursday.
The cancer drug Avastin could be as effective as the more expensive Lucentis at improving the vision of seniors with macular degeneration, according to a report from The New York Times.